In this episode, we explore the groundbreaking Neuro Direct technology that provides a new way of safely and effectively administering neuroeffective compounds without the side effects usually associated with oral or systemic administration. Dr. Ronald Ongdon invented the technology, and it has been used successfully for sumatryptin, a drug for severe migraines, and shows significant promise for the administration of ketamine for PTSD and depression. We'll learn about a recent observational study that showed an 80% favorable response rate to the neurodirect ketamine in an off-label format and how the cream's effectiveness can be seen immediately, unlike traditional SSRIs that require six weeks to take effect. We'll also discuss the risks associated with receiving treatments that haven't gone through the appropriate pathways, the urgency of effective treatments for mental health issues, and promising developments in clinical trials for the company's product. Additionally, we'll explore how Micro dosing with psychedelics like psilocybin and LSD has been gaining popularity, and how the guest's product may bring some of the benefits of microdosing to the market.